Protara Therapeutics, Inc. (TARA)
NASDAQ
2.50
+0.02 (+0.60%)
Closed
Oct 15, 2026
Day's Range
2.482.56
52 wk Range
2.477.82
Financial Statements - TARA - Protara Therapeutics, Inc.
Revenue
0
Net Income
-57.43M▼ 28.8%
EBITDA
-64.23M▼ 31.5%
Free Cash Flow
-56.45M▼ 57.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -64.54M | -49.15M | -43.61M | -37.54M | -47.48M | -34.44M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 779K | 423K | 12K | -29.50M | - | - |
| Pre Tax Income | -57.43M | -44.59M | -40.42M | -65.95M | -47.25M | -33.97M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -57.43M | -44.59M | -40.42M | -65.95M | -47.25M | -33.97M |
| EPS Basic | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | -4.7 |
| EPS Diluted | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 | -4.7 |
| Basic Shares Outstanding | 42.83M | 20.59M | 11.33M | 11.25M | 11.23M | 7.23M |
| Diluted Shares Outstanding | 42.83M | 20.59M | 11.33M | 11.25M | 11.23M | 7.23M |
| Ebit | -64.54M | -49.15M | -43.61M | -64.81M | -45.51M | -33.94M |
| Ebitda | -64.23M | -48.85M | -43.28M | -35.06M | -45.39M | -33.84M |
| Net Income Continuous Operations | -57.43M | -44.59M | -40.42M | -65.95M | -47.25M | -33.97M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
